IN2014DN09228A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN09228A IN2014DN09228A IN9228DEN2014A IN2014DN09228A IN 2014DN09228 A IN2014DN09228 A IN 2014DN09228A IN 9228DEN2014 A IN9228DEN2014 A IN 9228DEN2014A IN 2014DN09228 A IN2014DN09228 A IN 2014DN09228A
- Authority
- IN
- India
- Prior art keywords
- compounds
- ews
- ewing
- tumors
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261623349P | 2012-04-12 | 2012-04-12 | |
| PCT/US2013/036234 WO2013155341A1 (en) | 2012-04-12 | 2013-04-11 | Methods and compositions for treating ewings sarcoma family of tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09228A true IN2014DN09228A (de) | 2015-07-10 |
Family
ID=49328171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9228DEN2014 IN2014DN09228A (de) | 2012-04-12 | 2013-04-11 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9290449B2 (de) |
| EP (1) | EP2836481B1 (de) |
| JP (2) | JP6130491B2 (de) |
| KR (1) | KR102145835B1 (de) |
| CN (2) | CN104395288B (de) |
| AU (2) | AU2013245812B2 (de) |
| CA (1) | CA2869513C (de) |
| HK (1) | HK1207368A1 (de) |
| IL (1) | IL234993B (de) |
| IN (1) | IN2014DN09228A (de) |
| MX (1) | MX2014011583A (de) |
| NZ (2) | NZ700612A (de) |
| WO (1) | WO2013155341A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8232310B2 (en) | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| US9290449B2 (en) * | 2012-04-12 | 2016-03-22 | Georgetown University | Methods and compositions for treating Ewings sarcoma family of tumors |
| JP6389884B2 (ja) * | 2013-10-24 | 2018-09-12 | ジョージタウン・ユニバーシティＧｅｏｒｇｅｔｏｗｎ Ｕｎｉｖｅｒｓｉｔｙ | 癌を治療するための方法及び組成物 |
| EA032644B1 (ru) * | 2014-10-09 | 2019-06-28 | Онктернал Терапьютикс, Инк. | Производные индолинона и их применение |
| WO2016141167A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
| EP3265063A4 (de) | 2015-03-03 | 2018-11-07 | Cureport, Inc. | Doppelt beladene liposomale pharmazeutische formulierungen |
| JP6864379B2 (ja) * | 2016-03-31 | 2021-04-28 | オンターナル セラピューティック インコーポレイテッドＯｎｃｔｅｒｎａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | インドール類似体及びその使用 |
| EP3490553A4 (de) | 2016-07-29 | 2020-03-25 | Oncternal Therapeutics, Inc. | Verwendung von indolinonverbindungen |
| EP3558266B1 (de) | 2016-12-21 | 2022-03-30 | The Board of Regents of The University of Texas System | Altertoxin ii als selektiver hemmer der ewing-familie von tumorzellen |
| CN108186630B (zh) * | 2017-12-18 | 2020-07-31 | 温州医科大学 | 靛红类似物在制备抗肿瘤药物中的应用 |
| CN110870917B (zh) * | 2018-09-03 | 2022-03-15 | 上海市第一人民医院 | Ews或其上调剂在制备治疗糖尿病及防治糖尿病个体肿瘤发生的药物中的应用 |
| US20230000823A1 (en) * | 2021-06-09 | 2023-01-05 | University Of Rochester | Compounds and Methods for the Treatment of Acute Myelogenous Leukemia |
| CN114057626B (zh) * | 2021-12-07 | 2023-06-30 | 山东第一医科大学(山东省医学科学院) | 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物 |
| WO2023178040A2 (en) * | 2022-03-13 | 2023-09-21 | University Of Virginia Patent Foundation | Inhibitors of ews-fli1 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU583793B2 (en) | 1983-07-22 | 1989-05-11 | Du Pont Pharmaceuticals Company | Phenylquinolinecarboxylic acids and derivatives as antitumor agents |
| AU1648600A (en) | 1998-12-04 | 2000-06-26 | Neurosearch A/S | Use of isatin derivatives as ion channel activating agents |
| CN1155572C (zh) | 2001-01-19 | 2004-06-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 吲哚类衍生物及其抗肿瘤用途 |
| US20030157486A1 (en) | 2001-06-21 | 2003-08-21 | Graff Jonathan M. | Methods to identify signal sequences |
| US7674778B2 (en) | 2004-04-30 | 2010-03-09 | Alnylam Pharmaceuticals | Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine |
| AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| US20090217390A1 (en) | 2005-04-29 | 2009-08-27 | Fernando Lecanda Cordero | Non-human animal sarcoma model |
| WO2008046083A2 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
| EP2124910A4 (de) | 2006-12-29 | 2012-02-15 | Univ Georgetown | Targeting von ews-fli1 als antitumortherapie |
| US8232310B2 (en) | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| CA2684594C (en) * | 2007-04-20 | 2015-10-06 | The Research Foundation Of State University Of New York | Benzimidazoles and pharmaceutical compositions thereof for treating mycobacterium tuberculosis or francisella tulerensis infection |
| US8377992B2 (en) * | 2007-10-22 | 2013-02-19 | The Wistar Institute | TRBD-binding effectors and methods for using the same to modulate telomerase activity |
| US8710068B2 (en) | 2009-01-19 | 2014-04-29 | The Trustees Of The University Of Pennsylvania | Method of treating cancer using a survivin inhibitor |
| WO2012078519A2 (en) | 2010-12-06 | 2012-06-14 | Numerate, Inc. | 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2 |
| US9290449B2 (en) * | 2012-04-12 | 2016-03-22 | Georgetown University | Methods and compositions for treating Ewings sarcoma family of tumors |
| CN103435606A (zh) | 2013-08-22 | 2013-12-11 | 中国药科大学 | CDK2与GSK3β双重抑制剂及用途 |
| JP6389884B2 (ja) | 2013-10-24 | 2018-09-12 | ジョージタウン・ユニバーシティＧｅｏｒｇｅｔｏｗｎ Ｕｎｉｖｅｒｓｉｔｙ | 癌を治療するための方法及び組成物 |
| EA032644B1 (ru) | 2014-10-09 | 2019-06-28 | Онктернал Терапьютикс, Инк. | Производные индолинона и их применение |
-
2013
- 2013-04-11 US US14/388,671 patent/US9290449B2/en active Active
- 2013-04-11 JP JP2015505921A patent/JP6130491B2/ja active Active
- 2013-04-11 AU AU2013245812A patent/AU2013245812B2/en active Active
- 2013-04-11 NZ NZ700612A patent/NZ700612A/en unknown
- 2013-04-11 CA CA2869513A patent/CA2869513C/en active Active
- 2013-04-11 WO PCT/US2013/036234 patent/WO2013155341A1/en active Application Filing
- 2013-04-11 NZ NZ723971A patent/NZ723971A/en unknown
- 2013-04-11 EP EP13776244.9A patent/EP2836481B1/de active Active
- 2013-04-11 MX MX2014011583A patent/MX2014011583A/es active IP Right Grant
- 2013-04-11 KR KR1020147031650A patent/KR102145835B1/ko active IP Right Grant
- 2013-04-11 IN IN9228DEN2014 patent/IN2014DN09228A/en unknown
- 2013-04-11 CN CN201380030414.2A patent/CN104395288B/zh active Active
- 2013-04-11 CN CN201611030609.9A patent/CN107011242B/zh active Active
-
2014
- 2014-10-05 IL IL234993A patent/IL234993B/en active IP Right Grant
-
2015
- 2015-08-17 HK HK15107941.8A patent/HK1207368A1/xx unknown
-
2016
- 2016-02-10 US US15/040,840 patent/US9714222B2/en active Active
-
2017
- 2017-03-06 AU AU2017201507A patent/AU2017201507B2/en active Active
- 2017-04-13 JP JP2017080017A patent/JP6345301B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1207368A1 (en) | 2016-01-29 |
| AU2017201507A1 (en) | 2017-03-23 |
| CN107011242B (zh) | 2020-08-07 |
| MX2014011583A (es) | 2016-02-09 |
| JP6345301B2 (ja) | 2018-06-20 |
| KR102145835B1 (ko) | 2020-08-20 |
| CA2869513A1 (en) | 2013-10-17 |
| US9714222B2 (en) | 2017-07-25 |
| CA2869513C (en) | 2020-07-07 |
| EP2836481A1 (de) | 2015-02-18 |
| JP2017141290A (ja) | 2017-08-17 |
| US20150051260A1 (en) | 2015-02-19 |
| IL234993B (en) | 2019-02-28 |
| NZ700612A (en) | 2016-09-30 |
| EP2836481A4 (de) | 2015-11-18 |
| CN104395288B (zh) | 2016-12-14 |
| AU2013245812A1 (en) | 2014-11-13 |
| US9290449B2 (en) | 2016-03-22 |
| KR20150007311A (ko) | 2015-01-20 |
| NZ723971A (en) | 2018-01-26 |
| US20160159741A1 (en) | 2016-06-09 |
| WO2013155341A1 (en) | 2013-10-17 |
| AU2017201507B2 (en) | 2018-10-04 |
| AU2013245812A2 (en) | 2014-11-20 |
| CN104395288A (zh) | 2015-03-04 |
| JP2015512943A (ja) | 2015-04-30 |
| JP6130491B2 (ja) | 2017-05-17 |
| CN107011242A (zh) | 2017-08-04 |
| EP2836481B1 (de) | 2018-12-26 |
| AU2013245812B2 (en) | 2017-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09228A (de) | ||
| PH12019502809A1 (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
| MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| MX366804B (es) | Translocaciones de la r-espondina y sus metodos de uso. | |
| MX2013004761A (es) | Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas. | |
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| UA109464C2 (uk) | Спірооксіндольні антагоністи mdm2 | |
| MY176489A (en) | Novel tricyclic compounds as anticancer agents | |
| MX2015014234A (es) | Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1. | |
| MX2015005963A (es) | Inhibidores heterociclicos de glutaminasa. | |
| EA201590987A1 (ru) | Соединения и способы их применения | |
| TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
| PH12015500186A1 (en) | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib | |
| MX357391B (es) | Anticuerpos anti-erbb3 y usos de los mismos. | |
| MX2019008122A (es) | Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1. | |
| GB201106743D0 (en) | Novel compounds | |
| MX2015010125A (es) | Derivados de piridazinona-amidas. | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| IN2014DN06104A (de) | ||
| PH12015501088A1 (en) | Dimeric compounds | |
| NZ628433A (en) | Chitosan-derived compositions | |
| MX2012013527A (es) | Quinazolinas policíclicas, preparación de las mismas, y uso de las mismas. | |
| MX2012012744A (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores. |